Bevacizumab/PD-1 inhibitor plus chemotherapy as first-line treatment of advanced non-squamous non-small-cell lung cancer

AIMS: To compare the effectiveness of PD-1 inhibitor or bevacizumab plus chemotherapy in advanced non-squamous non-small cell lung cancer (nsNSCLC). METHODS: We retrospectively collected data for patients with advanced nsNSCLC who underwent first-line treatment with PD-1 inhibitor or bevacizumab plu...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Jing, Chen, Qin, Wang, Xinyue, Huang, Dingzhi, Jiang, Richeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Becaris Publishing Ltd 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10402762/
https://www.ncbi.nlm.nih.gov/pubmed/37067955
http://dx.doi.org/10.57264/cer-2023-0006

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10402762/
https://www.ncbi.nlm.nih.gov/pubmed/37067955
http://dx.doi.org/10.57264/cer-2023-0006

Ejemplares similares